Stephanie Saucier, MD
Cardiovascular Disease · Hartford, CTNPI 1548680309
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 74.0% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $114,191, more than ten times the $1,701 reported in 2019. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 363 payments — averaging $669.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$180K
- Novartis$56K
- Kaneka Medical America LLC$3K
- Johnson & Johnson$768
- Novo Nordisk$665
- Abbott$574
- plus $2K from 18 others
Across 7 payments — averaging $11,569 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$61K
- Amgen$20K
What the payments were for
- Consulting fees$64,98827%
- Speaking & faculty fees$120,93650%
- Travel & lodging$42,24417%
- Food & beverage$14,5316%
- Education$3790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 219 | $179,971 |
| Novartis | 62 | $56,151 |
| Kaneka Medical America LLC | 1 | $2,500 |
| Johnson & Johnson | 11 | $768 |
| Novo Nordisk | 9 | $665 |
| Abbott | 6 | $574 |
| Lilly USA, LLC | 10 | $484 |
| Boehringer Ingelheim | 7 | $391 |
| AstraZeneca | 7 | $382 |
| Medtronic | 1 | $149 |
| Pfizer | 3 | $140 |
| Alnylam Pharmaceuticals Inc. | 2 | $126 |
| E.r. Squibb & Sons, L.L.C. | 5 | $121 |
| Ionis Pharmaceuticals, Inc. | 1 | $121 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $120 |
| Impulse Dynamics (USA) Inc. | 1 | $116 |
| Astellas Pharma US Inc | 1 | $100 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $68 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Chiesi USA, Inc. | 1 | $24 |
| CSL Behring | 1 | $23 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $13 |
| Akcea Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$135,279
- LEQVIO$34,126
- Fabhalta$9,857
- ENTRESTO$9,411
- Apheresis Machine$2,500
- XARELTO$608
- Ozempic$365
- OPTIMIZER$233
- HeartMate 3 Left Ventricular Dev$183
- AURORA EV-ICD MRI SURESCAN$149
- CARDIOMEMS$129
- JARDIANCE$125
- BRILINTA$124
- TRYNGOLZA$121
- CardioMEMS HF System$115
- VYNDAQEL$113
- ONPATTRO$111
- MOUNJARO$104
How this compares
$243,077 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 1,166 | $771,309 |
| Praluent PenAlirocumab | 478 | $268,474 |
| EliquisApixaban | 128 | $151,659 |
| LeqvioInclisiran Sodium | 36 | $115,434 |
| JardianceEmpagliflozin | 77 | $73,087 |
| NexletolBempedoic Acid | 95 | $68,579 |
| XareltoRivaroxaban | 35 | $58,572 |
| MounjaroTirzepatide | 44 | $56,902 |
| EntrestoSacubitril/Valsartan | 65 | $52,187 |
| OzempicSemaglutide | 41 | $49,083 |
| VascepaIcosapent Ethyl | 57 | $35,893 |
| NexlizetBempedoic Acid/Ezetimibe | 37 | $28,637 |
| WegovySemaglutide | 18 | $23,447 |
| BrilintaTicagrelor | 24 | $22,137 |
| Icosapent Ethyl | 46 | $12,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisLeqvio, Entresto | $56,151 | $167,621101 claims |
| PfizerEliquis | $140 | $151,659128 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $41 | $97,216132 claims |
| Boehringer IngelheimJardiance | $391 | $73,08777 claims |
| Novo NordiskOzempic, Wegovy | $665 | $72,52959 claims |
| Johnson & JohnsonXarelto | $768 | $58,57235 claims |
| Lilly USA, LLCMounjaro | $484 | $56,90244 claims |
| AstraZenecaBrilinta | $382 | $22,13724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Hartford
- Antonio FernandezHartford$113K
- Paul ThompsonHartford$108K
- Richard SoucierHartford$97K
- Atique MirzaHartford$29K
- Sean McMahonHartford$23K
- Lonny ReismanHartford$22K
- David HenryHartford$13K
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.